Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.69 |
| ▸ | IKZF2 | Q9UKS7 | 10/20 | 0.57 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30569130 | 1.00 | CRBN (0.69) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL30569011 | 0.92 | CRBN (0.62) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL21759952 | 0.92 | CRBN (0.71) | CRBN | |
| SCHEMBL29873934 | 0.88 | CRBN (0.62) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL23250036 | 0.88 | CRBN (0.62) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL24046320 | 0.88 | CRBN (0.62) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL20129298 | 0.88 | CRBN (0.62) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL23267271 | 0.87 | CRBN (0.64) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL21877059 | 0.87 | CRBN (0.64) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL25756473 | 0.86 | CRBN (0.61) | CRBNIKZF2CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220722-A2 | PAK1 DEGRADERS AND METHODS OF USE THEREOF | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230011665-A1 | SELECTIVE HDAC6 DEGRADERS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011665-A1 | SELECTIVE HDAC6 DEGRADERS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC11 | CRBN 1341/4885IKZF2 147/4885CSNK1A1 1210/4885 |
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | ALK, ERBB2, PDGFRB | CRBN 500/4885IKZF2 2046/4885CSNK1A1 861/4885 |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | EGFR, ERBB2, ERBB3 | CRBN 3528/4885IKZF2 3455/4885CSNK1A1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.